Literature DB >> 28950320

Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: to continue or not to continue.

S T Butterbaugh1, R Patel1, E H Romond1, A Mathew1,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28950320     DOI: 10.1093/annonc/mdx532

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

1.  No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer.

Authors:  Zachary Veitch; Domen Ribnikar; Derek Tilley; Patricia A Tang; Karen King; Philippe L Bedard; Sasha Lupichuk; David W Cescon
Journal:  Br J Cancer       Date:  2021-12-20       Impact factor: 9.075

2.  Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review.

Authors:  Chaokun Wang; Jing Chen; Xiangyun Xu; Xiaochen Hu; Dejiu Kong; Gaofeng Liang; Xinshuai Wang
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.